Publicaciones científicas

29 Publicaciones científicas disponibles

  • Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients

    23 de julio de 2019 | Revista: Journal of Thoracic Oncology

    Conde E (1), Hernandez S (2), Martinez R (2), Angulo B (1), De Castro J (3), Collazo-Lorduy A (2), Jimenez B (2), Muriel A (4), Mate JL (5), Moran T (6), Aranda I (7), Massuti B (7), Rojo F (8), Domine M (9), Sansano I (10), Garcia F (11), Felip E (10), Mancheño N (12), Juan O (12), Sanz J (13), Gonzalez-Larriba JL (13), Atienza-Cuevas L (14), Arriola-Arellano E (14), Abdulkader I (15), Garcia-Gonzalez J (15), Camacho C (16), Rodriguez-Abreu D (16), Teixido C (17), Reguart N (17), Gonzalez-Piñeiro A (18), Lazaro-Quintela M (18), Lozano MD (19), Gurpide A (19), Gomez-Roman J (20), Lopez-Brea M (20), Pijuan L (21), Salido M (21), Arriola E (21), Company A (22), Insa A (22), Esteban-Rodriguez I (3), Saiz M (23), Azkona E (23), Alvarez R (24), Artal A (24), Plaza ML (25), Aguiar D (25), Enguita AB (26), Benito A (27), Paz-Ares L (28), Garrido P (29), Lopez-Rios F (30)

    (1) Hospital Universitario HM Sanchinarro-CIBERONC, Madrid. Spain.
    (2) Hospital Universitario HM Sanchinarro, Madrid. Spain.
    (3) Hospital Universitario La Paz, Madrid. Spain.
    (4) Hospital Universitario Ramon y Cajal, IRYCIS and CIBERESP, Madrid. Spain.
    (5) Hospital Universitari Germans Trias i Pujol, Badalona. Spain.
    (6) Instituto Catalan de Oncologia-Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona-Apllied Research Group of Oncology (B-ARGO), Badalona. Spain.
    (7) Hospital General Universitario-ISABIAL, Alicante. Spain.
    (8) Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz-CIBERONC, Madrid. Spain.
    (9) Instituto de Investigacion Sanitaria-Fundacion Jimenez Diaz, Madrid. Spain.
    (10) Hospital Universitari Vall d'Hebron, Barcelona. Spain.
    (11) Hospital Quironsalud, Barcelona. Spain.
    (12) Hospital Universitario La Fe, Valencia. Spain.
    (13) Hospital Clinico Universitario San Carlos, Madrid. Spain.
    (14) Hospital Universitario Puerta del Mar, Cadiz. Spain.
    (15) Hospital Clinico Universitario de Santiago, Santiago De Compostela.
    Spain.
    (16) Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas De Gran Canaria. Spain.
    (17) Hospital Clinic, Barcelona. Spain.
    (18) Hospital Alvaro Cunqueiro, Vigo. Spain.
    (19) Clinica Universidad de Navarra, Pamplona. Spain.
    (20) Hospital Universitario Marques de Valdecilla, Santander. Spain.
    (21) Hospital del Mar, Barcelona. Spain.
    (22) Hospital Clinico Universitario, Valencia. Spain.
    (23) Hospital Universitario de Cruces, Baracaldo. Spain.
    (24) Hospital Universitario Miguel Servet, Zaragoza. Spain.
    (25) Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria. Spain.
    (26) Hospital Universitario 12 de Octubre, Madrid. Spain.
    (27) Hospital Universitario Ramon y Cajal, Madrid. Spain.
    (28) Hospital Universitario 12 de Octubre-CIBERONC, Madrid. Spain.
    (29) Hospital Universitario Ramon y Cajal-CIBERONC, Madrid. Spain.
    (30) Hospital Universitario HM Sanchinarro-CIBERONC, Madrid. Spain.


  • Identification of mutations associated with acquired resistance to sunitinib in renal cell-cancer

    8 de marzo de 2019 | Revista: International Journal of Cancer

    Elgendy M (1,2), Fusco JP (3,4), Segura V (5), Lozano MD (4,6,7), Minucci S (1,8), Echeveste JI (4,6), Gurpide A (3,4), Andueza M (3,4), Melero I (4,7,9), Sanmamed MF (3,4), Ruiz MR (3,4), Calvo A (4,10), Pascual JI (4,11), Velis JM (4,11), Miñana B (4,11), Valle RD (4,12), Pio R (4,7,13), Agorreta J (4,7,13), Abengozar M (4,6), Colecchia M (14), Brich S (14), Renne SL (14), Guruceaga E (5), Patiño-García A (4,13,15), Perez-Gracia JL (3,4,7).

    (1) Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy.
    (2) Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
    (3) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
    (4) Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
    (5) IDISNA and Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Navarra, Spain.
    (6) Pathology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
    (8) Department of Biosciences, University of Milan, Milan, Italy.
    (9) Department of Immunology, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (10) Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Navarra, Spain.
    (11) Department of Urology, Clinica Universidad de Navarra, Pamplona and Madrid, Spain.
    (12) Department of Neurosurgery, University Clinic of Navarra, Pamplona, Spain.
    (13) Program in Solid Tumors. Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (14) Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
    (15) Department of Pediatrics and Clinical Genetics, Clinica Universidad de Navarra, Pamplona, Spain.


  • The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

    23 de enero de 2019 | Revista: Disease Markers

    Macías M (1), Alegre E (1,2), Alkorta-Aranburu G (3), Patiño-García A (2,3,4), Mateos B (1), Andueza MP (5), Gúrpide A (2,5), Lopez-Picazo JM (2,5), Gil-Bazo I (2,5,6), Perez-Gracia JL (2,5), González Á (1,2).

    (1) Service of Biochemistry, Clínica Universidad de Navarra, Av. Pio XII 36 Pamplona 31008, Spain.
    (2) Navarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
    (3) Unit of Genomics, CIMA LAB Diagnostics, University of Navarra, Av. Pio XII 55 31008 Pamplona, Spain.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, Av. Pio XII 36 31008 Pamplona, Spain.
    (5) Department of Oncology, Clínica Universidad de Navarra, Av. Pio XII 36 31008 Pamplona, Spain.
    (6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029 Madrid Madrid, Spain.


  • Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    1 de agosto de 2017 | Revista: Annals of Oncology

    Sanmamed MF (1), Perez-Gracia JL (2,3), Schalper KA (4,5), Fusco JP (2), Gonzalez A (3,6), Rodriguez-Ruiz ME (2,7), Oñate C (2), Perez G (2), Alfaro C (2,3), Martín-Algarra S (2), Andueza MP (2), Gurpide A (2), Morgado M (4), Wang J (1), Bacchiocchi A (8), Halaban R (8), Kluger H (5), Chen L (1), Sznol M (5), Melero I (2,6,7).

    (1) Department of Immunobiology, Yale University School of Medicine, New Haven, USA.
    (2) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) CIBERONC (Centro de Investigación Biomedica en Red de Cáncer).
    (4) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
    (5) Comprehensive Cancer Center Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA.
    (6) Department of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Spain.
    (8) Department of Dermatology, Yale University School of Medicine, New Haven, USA.

No hay más publicaciones científicas

No hay más páginas para cargar